drugset / Trial / NCT00602706

Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

NCT00602706

Phase 1/2 Completed 76 enrolled Mayo Clinic National Cancer Institute (NCI) · collab
Treatment

Summary

RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells either by killing the cells or by stopping them from dividing. Samarium Sm 153 lexidronam pentasodium contains a radioactive substance that kill cancer cells. Peripheral blood stem cell transplant using stem cells from the patient may be able to replace immune cells that were destroyed by chemotherapy and radioactive drugs used to kill cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of samarium Sm 153 lexidronam pentasodium when given together with high-dose melphalan in treating patients with multiple myeloma undergoing stem cell transplant.

Timeline

Start
2000-01
Primary completion
2003-06
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Background Melphalan Small molecule Intravenous
Background sargramostim Protein / enzyme biologic Subcutaneous

Indications